Browsing by Author "Mayxay M."
Now showing 1 - 20 of 46
- Results Per Page
- Sort Options
Item Metadata only A repetitive nucleotide insertion in the rplV gene is associated with in vitro resistance to azithromycin in Rickettsia typhi(2026-04-01) Phuklia W.; Chowongkomon K.; Padith K.; Phommasone K.; Mayxay M.; Richards A.L.; Batty E.M.; Robinson M.T.; Newton P.N.; White N.J.; Day N.P.J.; Ashley E.A.; Phuklia W.; Mahidol UniversityBACKGROUND: Murine typhus, caused by Rickettsia typhi, is a treatable febrile illness in Laos, where azithromycin treatment failure has been reported. Antibiotic susceptibility testing for Rickettsia spp. is challenging due to absence of resistant strains. We aimed to induce an azithromycin-resistant in R. typhi and investigate its genetic basis. METHODOLOGY: R. typhi Wilmington was cultured in azithromycin-containing media (R. typhiAZM), starting at a concentration of 0.0019 mg/L and gradually increased to 0.0625 mg/L. Resistant populations were selected up to 0.125 mg/L. MICs were determined using plaque assay and qPCR, and DNA sequencing was performed for rplD (L4), rplV (L22), and 23S rRNA domain V. Protein modeling of azithromycin-binding sites was conducted, and strain stability was assessed over 24 passages without azithromycin (R. typhi AZM (-)). RESULTS: MICs for wild type (R. typhiWT) and R. typhiAZM were 2 mg/L versus >16 mg/L (plaque assay) and 0.25 mg/L versus 8 mg/L (qPCR). A 15-nucleotides insertion (5'-AAAGGAAGAGCAACT-3') was found in the rplV of R. typhiAZM, but not other isolates. Protein modeling suggested the insertion extends the L22 loop, potentially affecting azithromycin binding site within the ribosomal exit tunnel. R. typhiAZM reverted to wild type MIC and genotype by 24 passages without azithromycin. R. typhiAZM exhibited an 8 -fold higher MIC than R. typhiWT. CONCLUSION: Repetitive insertion in rplV was associated with azithromycin resistance and may interfere with drug binding. R. typhiAZM was unstable without selective pressure. This approach may help generate resistant strains for assay validation. The role of rplV mutations in azithromycin susceptibility warrants further investigation.Item Metadata only A target product profile and roadmap for Japanese encephalitis diagnostics in endemic areas in the context of other flaviviruses(2026-09-01) Bharucha T.; Stokes L.; Anane-Amponsah D.; Abraham A.M.; Auewarakul P.; Awal B.; Belludi A.Y.; Bondre V.; Damodar T.; de Lamballerie X.; Dhodapkar R.; Dubot-Pérès A.; Duong V.; Easton A.; Evans R.; Grabovac V.; Gupta N.; Huong N.H.T.; Khan S.A.; Kinhal U.V.; Krishnasamy K.; Lim C.K.; Lodha L.; Malavige G.N.; Mammen S.; Mayxay M.; Miraclin T A.; Mukhopadhyay L.; Mulders M.; Munivenkatappa A.; Noronha A.K.; Ooi M.H.; Otter A.; Pasco P.; Pattassery S.A.; Radera S.; Gowda V.K.; Reddy V.; Rupali P.; Saravu K.; Sangal L.; Saysanasongkham S.; Shakoor S.; Srinavasan K.; Sultana S.; M A A.; Singh B.; Solomon T.; S Y A.K.; Van Tan L.; Tetteh K.K.A.; Trung T.H.; Turtle L.; Vasanthapuram R.; Venkataswamy M.M.; Vu N.T.; Wilkinson R.J.; Zangmo S.; Mani R.; Dittrich S.; Bharucha T.; Mahidol UniversityJapanese encephalitis (JE) virus (JEV) is a leading cause of neurological infection in the Asia-Pacific region with devastating socioeconomic consequences. We aimed to develop a target product profile (TPP) for JE diagnostics in endemic areas in the context of other flaviviruses, to better define improvements needed for patient management and public health. Thematic experts were identified from a scoping review, World Health Organization and Encephalitis International databases, as well as author networks. Initial interviews were performed with selected experts to inform a draft TPP document and start a Delphi process, aiming for consensus of ≥75% on each characteristic. A one-day meeting facilitated in-depth discussion, with breakout groups and electronic voting to develop the final TPP document. In total, 460 participants were invited. Five interviews enabled drafting a TPP. Two iterative surveys were completed by 44 respondents, including clinicians, scientists, and public health experts from 15 countries. A hybrid meeting was attended by 42 participants. Seven priority characteristics were discussed, and consensus was achieved for six; no clear consensus was reached for the preferred test sensitivity and specificity, with 73% agreement. Discussion points and areas of expert consensus were consolidated into a roadmap for development and implementation to guide future work. A diverse group of health professionals agreed that improved diagnostics for JE are needed, and that a priority is a test for patient management that detects JE alongside other relevant flavivirus infections. There was a mandate for a rapid diagnostic test (RDT), and it was suggested that this could be implemented in a two-tiered diagnostic algorithm. The final TPP is presented in the paper; this aims to help define the updates needed to better support patient management and public health interventions, to provide a strategic reference document to drive innovation and improve clarity for JE diagnostic test developers.Item Metadata only Accuracy and Usability of a New Rapid Diagnostic Test for the Diagnosis of Dengue in Vientiane, Laos(2026-07-01) Phimolsannousith V.; Sibounheuang B.; Chanthongthip A.; Vongsouvath M.; Mayxay M.; Mukaka M.; Luangraj M.; Newton P.N.; Ashley E.A.; Hopkins H.; Dubot-Pérès A.; Phimolsannousith V.; Mahidol UniversityBackground: An estimated 390 million dengue virus (DENV) infections occur per year, 70% in the Western Pacific and Southeast Asia. A prototype rapid diagnostic test (RDT) (NS1, immunoglobulin M [IgM]/immunoglobulin G [IgG]; DengueDx, Mologic) was evaluated for accuracy and ease of use for dengue diagnosis at Mahosot Hospital, Vientiane, Lao People’s Democratic Republic. Methods: Five hundred twenty-six sera collected in 2017 and 2018 from patients hospitalized with suspected dengue were included. Prototype RDT results were compared to NS1 and IgM enzyme-linked immunosorbent assays and/or real-time reverse-transcription polymerase chain reaction as reference assays and to Bioline dengue RDT (NS1, IgM/IgG) as comparator. The accuracy of the image-based result interpretation (RDT scan or photograph) at day 0 and after a delay of 7 days was evaluated. Five technicians were observed when performing RDTs and interviewed on their perception of the ease of use. Results: The overall sensitivity and the sensitivity for NS1 detection alone were significantly lower for the prototype RDT (65.2% [95% confidence interval {CI}, 59.3%–70.8%] and 44.6% [95% CI, 38.0%–51.4%], respectively) than for the Bioline RDT (76.7% [95% CI, 69.1%–83.2%], z-test P = .014; and 66.7% [95% CI, 57.5%–75.0%], z-test P < .001, respectively). The positive predictive value of the prototype RDT for detection of NS1 was >90%. Only half of the positive results were found positive when reading results from images. Correlation of >98% for positive results was obtained between reading at day 0 and reading at day 7. During ease of use assessment, when performing the Bioline RDTs the participants made fewer errors and were more satisfied than when performing the prototype RDTs. Conclusions: Improvement in test sensitivity and in device design would adapt the prototype RDT for Laos and similar contexts. Optimization of the prototype RDT is warranted and further evaluation in different healthcare settings would provide a more accurate estimation of the value of this RDT for dengue surveillance in remote areas.Item Metadata only Adherence to smartphone-delivered antimicrobial prescribing guidelines in hospitals in Lao PDR: A stepped-wedge cluster randomized controlled trial(2026-01-01) Chansamouth V.; Chommanam D.; Lee S.J.; Vongphachanh S.; Vongsouvath M.; Keomany S.; Paphasiri V.; Phamisith C.; Sengsavang S.; Douangdala P.; Detleuxay K.; Rattana S.; Soumphonphakdy B.; Keoluangkhot V.; Mukaka M.; Day N.P.J.; van Doorn H.R.; Turner P.; Mayxay M.; Newton P.N.; Ashley E.A.; Chansamouth V.; Mahidol UniversityBackground: Prescribing guidelines are a cornerstone of antimicrobial stewardship programs. Smartphone applications can increase access in low-and middle-income countries (LMICs). Following the release of the Lao national antimicrobial prescribing guidelines in 2021, this trial compared adherence to these guidelines delivered by a smartphone application versus the paper-based version among hospitalized patients and outpatients in six hospitals in Laos. Methods and findings: An open cohort stepped-wedge cluster randomized controlled 3-step trial was conducted from 2021–2022. The intervention was a smartphone application-based prescribing guideline and antimicrobial stewardship (AMS) training. The reference was a paper-based version of the same guidelines. Adherence was defined as prescriptions using the correct antimicrobial(s) and correct dose based on the provided prescribing guidelines. The primary outcome was assessed via repeated point prevalence surveys (PPS) at ~4-month intervals. Data were analyzed using a mixed-effects regression model, accounting for time and clustering. Among 3,561 hospitalized patient prescriptions, overall guideline adherence was 17.0% (95% confidence interval or CI [15.0,19]) in the reference group, and 25.6% (95% CI [23.1,28.3]) in the intervention group. After accounting for time and cluster effects and adjusting for confounders (sequence of intervention, age, gender, prescribing indication, and hospital department), adherence did not differ by guideline delivery mode (adjusted odds ratio (aOR)=1.26 (95% CI [0.8,1.9]; p = 0.276). Similar findings were observed in outpatient settings (aOR = 0.91 (95% CI [0.7,1.1]; p = 0.406)). Outpatient adherence varied by time of intervention introduction, with the first group of hospitals exposed to the intervention showing higher odds of adherence (32.1% [302/940]; 95% CI [29.1,35.2]) compared with the last group (19.1% [241/1,261]; 95% CI [16.9,21.4]) with aOR = 1.95 (95% CI [1.4,2.7]; p < 0.001). Prescribing in this study was assessed using patients’ medical records; as prescriptions could not be reliably linked to individual prescribers, changes in individual prescribing behavior could not be evaluated. Conclusion: This study demonstrated that smartphone technology can deliver antimicrobial prescribing guidelines in an LMIC like Laos. However, the trial did not demonstrate the pre-specified improvement in guidelines adherence with the smartphone app and AMS training compared with paper-based guidelines. While treatment guidelines underpin antimicrobial stewardship efforts, adherence depends on multiple factors beyond guideline availability. The trial was registered at clinicaltrials.gov (NCT04914793).Item Metadata only Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study(2022-04-07) O’Flaherty K.; Chan J.A.; Cutts J.C.; Zaloumis S.G.; Ashley E.A.; Phyo A.P.; Drew D.R.; Dondorp A.M.; Day N.P.; Dhorda M.; Fairhurst R.M.; Lim P.; Amaratunga C.; Pukrittayakamee S.; Hien T.T.; Htut Y.; Mayxay M.; Faiz M.A.; Mokuolu O.A.; Onyamboko M.A.; Fanello C.; Takashima E.; Tsuboi T.; Theisen M.; Nosten F.; Beeson J.G.; Simpson J.A.; White N.J.; Fowkes F.J.I.; Mahidol UniversityIntroduction: Understanding the human immune response to Plasmodium falciparum gametocytes and its association with gametocytemia is essential for understanding the transmission of malaria as well as progressing transmission blocking vaccine candidates. Methods: In a multi-national clinical efficacy trial of artemisinin therapies (13 sites of varying transmission over South-East Asia and Africa), we measured Immunoglobulin G (IgG) responses to recombinant P. falciparum gametocyte antigens expressed on the gametocyte plasma membrane and leading transmission blocking vaccine candidates Pfs230 (Pfs230c and Pfs230D1M) and Pfs48/45 at enrolment in 1,114 participants with clinical falciparum malaria. Mixed effects linear and logistic regression were used to determine the association between gametocyte measures (gametocytemia and gametocyte density) and antibody outcomes at enrolment. Results: Microscopy detectable gametocytemia was observed in 11% (127/1,114) of participants at enrolment, and an additional 9% (95/1,114) over the follow-up period (up to day 42) (total 20% of participants [222/1,114]). IgG levels in response to Pfs230c, Pfs48/45 and Pfs230D1M varied across study sites at enrolment (p < 0.001), as did IgG seroprevalence for anti-Pfs230c and D1M IgG (p < 0.001), but not for anti-Pfs48/45 IgG (p = 0.159). In adjusted analyses, microscopy detectable gametocytemia at enrolment was associated with an increase in the odds of IgG seropositivity to the three gametocyte antigens (Pfs230c OR [95% CI], p: 1.70 [1.10, 2.62], 0.017; Pfs48/45: 1.45 [0.85, 2.46], 0.174; Pfs230D1M: 1.70 [1.03, 2.80], 0.037), as was higher gametocyte density at enrolment (per two-fold change in gametocyte density Pfs230c OR [95% CI], p: 1.09 [1.02, 1.17], 0.008; Pfs48/45: 1.05 [0.98, 1.13], 0.185; Pfs230D1M: 1.07 [0.99, 1.14], 0.071). Conclusion: Pfs230 and Pfs48/45 antibodies are naturally immunogenic targets associated with patent gametocytemia and increasing gametocyte density across multiple malaria endemic settings, including regions with emerging artemisinin-resistant P. falciparum.Item Metadata only Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial(2024-01-01) Schilling W.H.K.; Jittamala P.; Watson J.A.; Boyd S.; Luvira V.; Siripoon T.; Ngamprasertchai T.; Batty E.M.; Cruz C.; Callery J.J.; Singh S.; Saroj M.; Kruabkontho V.; Ngernseng T.; Tanglakmankhong N.; Tubprasert J.; Abdad M.Y.; Madmanee W.; Kouhathong J.; Suwannasin K.; Pagornrat W.; Piaraksa N.; Hanboonkunupakarn P.; Hanboonkunupakarn B.; Poovorawan K.; Potaporn M.; Srisubat A.; Loharjun B.; Taylor W.R.J.; Chotivanich V.; Chotivanich K.; Imwong M.; Pukrittayakamee S.; Dondorp A.M.; Day N.P.J.; Teixeira M.M.; Piyaphanee W.; Phumratanaprapin W.; White N.J.; Schilling W.H.K.; Day N.P.J.; Taylor W.R.J.; Thaipadungpanit J.; Ekkapongpisit M.; Ruksakul W.; Sangketchon C.; Sookprome S.; Teixeira M.M.; Almeida P.J.; Aguiar R.S.; Santos F.; Ashley E.; Vongsouvath M.; Phommasone K.; Dubot-Pérès A.; Vidhamaly S.; Chingsanoon A.; Bisayher S.; Chommanam D.; Evans T.J.; Vidhamaly V.; Boutthasavong L.; Mayxay M.; Schilling W.H.K.; Mahidol UniversityBackground: Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their antiviral activities in patients have not been compared directly. The aim of this ongoing platform trial is to compare different antiviral treatments using the rate of viral clearance as the measure of antiviral effect. Methods: PLATCOV is an open-label, multicentre, phase 2, randomised, controlled, adaptive pharmacometric platform trial running in Thailand, Brazil, Pakistan, and Laos. The component of the trial reported here was conducted in the Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. We recruited low-risk adult patients aged 18–50 years with early symptomatic COVID-19 (<4 days of symptoms). Eligible patients were randomly assigned using block randomisation via a centralised web app to one of seven treatment groups: molnupiravir, ritonavir-boosted nirmatrelvir, casirivimab–imdevimab, tixagevimab–cilgavimab, favipiravir, fluoxetine, or no study drug. The no study drug group comprised a minimum proportion of 20% of patients at all times, with uniform randomisation ratios applied across the active treatment groups. Results for the concurrently randomised molnupiravir, ritonavir-boosted nirmatrelvir, and no study drug groups are reported here. The primary endpoint was the rate of oropharyngeal viral clearance assessed in a modified intention-to-treat population, defined as patients with more than 2 days of follow-up. Safety was assessed in all participants who took at least one dose of the medication. The viral clearance rate was derived under a Bayesian hierarchical linear model fitted to the log10 viral densities in standardised duplicate oropharyngeal swab eluates taken daily over 1 week (18 measurements). Treatment groups with a probability of more than 0·9 that viral clearance was accelerated by more than 20% compared with no drug entered a non-inferiority comparison (with a 10% non-inferiority margin) compared with the platform's current most effective drug. This ongoing trial is registered at ClinicalTrials.gov, NCT05041907. Findings: Between June 6, 2022, and Feb 23, 2023, 209 patients in Thailand were enrolled and concurrently randomly assigned to molnupiravir (n=65), ritonavir-boosted nirmatrelvir (n=59), or no study drug (n=85). 129 (62%) of the patients were female and 80 (38%) were male. Relative to the no study drug group, the rates of viral clearance were 37% (95% credible interval 16–65) faster with molnupiravir and 84% (54–119) faster with ritonavir-boosted nirmatrelvir. In the non-inferiority comparison, viral clearance was 25% (10–38) slower with molnupiravir than ritonavir-boosted nirmatrelvir. Molnupiravir was removed from the study platform when it reached the prespecified inferiority margin of 10% compared with ritonavir-boosted nirmatrelvir. Median estimated viral clearance half-lives were 8·5 h (IQR 6·7–10·1) with ritonavir-boosted nirmatrelvir, 11·6 h (8·6–15·4) with molnupiravir, and 15·5 h (11·9–21·2) with no study drug. Viral rebound occurred more frequently following nirmatrelvir (six [10%] of 58) compared with the no study drug (one [1%] of 84; p=0·018) or the molnupiravir (one [2%] of 65; p=0·051) groups. Persistent infections following molnupiravir had more viral mutations (three of nine patients had an increased number of single nucleotide polymorphisms in samples collected at 7 or more days compared with those at baseline) than after nirmatrelvir (zero of three) or no study drug (zero of 19). There were no adverse events of grade 3 or worse, or serious adverse events in any of the reported treatment groups. Interpretation: Both molnupiravir and ritonavir-boosted nirmatrelvir accelerate oropharyngeal SARS-CoV-2 viral clearance in patients with COVID-19, but the antiviral effect of ritonavir-boosted nirmatrelvir was substantially greater. Measurement of oropharyngeal viral clearance rates provides a rapid and well tolerated approach to the assessment and comparison of antiviral drugs in patients with COVID-19. It should be evaluated in other acute viral respiratory infections. Funding: Wellcome Trust through the COVID-19 Therapeutics Accelerator.Item Metadata only Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response(2022-12-01) Zhu L.; van der Pluijm R.W.; Kucharski M.; Nayak S.; Tripathi J.; White N.J.; Day N.P.J.; Faiz A.; Phyo A.P.; Amaratunga C.; Lek D.; Ashley E.A.; Nosten F.; Smithuis F.; Ginsburg H.; von Seidlein L.; Lin K.; Imwong M.; Chotivanich K.; Mayxay M.; Dhorda M.; Nguyen H.C.; Nguyen T.N.T.; Miotto O.; Newton P.N.; Jittamala P.; Tripura R.; Pukrittayakamee S.; Peto T.J.; Hien T.T.; Dondorp A.M.; Bozdech Z.; Mahidol UniversityThe emergence and spread of artemisinin-resistant Plasmodium falciparum, first in the Greater Mekong Subregion (GMS), and now in East Africa, is a major threat to global malaria elimination ambitions. To investigate the artemisinin resistance mechanism, transcriptome analysis was conducted of 577 P. falciparum isolates collected in the GMS between 2016–2018. A specific artemisinin resistance-associated transcriptional profile was identified that involves a broad but discrete set of biological functions related to proteotoxic stress, host cytoplasm remodelling, and REDOX metabolism. The artemisinin resistance-associated transcriptional profile evolved from initial transcriptional responses of susceptible parasites to artemisinin. The genetic basis for this adapted response is likely to be complex.Item Metadata only Assessing public health training in Southeast Asia and the United Kingdom: A comparison of competency development for delivering the Essential Public Health Functions(2026-04-01) Ong S.K.; Hamilton K.; Razavi A.; Ngan T.T.; Yi S.; Sreeramareddy C.T.; Bulgiba A.; Antonio C.A.; Tar Lim R.B.; Khuon D.; Sotheara H.; Mayxay M.; Win H.H.; Kalampakorn S.; Septiono W.; Latif S.; Kassim N.; Lee Jen Mai J.; Liow C.H.; Wong S.Y.S.; Kok K.; Ong S.K.; Mahidol UniversityObjectives This study mapped public health training programmes across the 10 ASEAN (the Association of Southeast Asian Nations) countries to assess their scope, capacity, and alignment with national and regional health needs, considering both medical and non-medical tracks. The United Kingdom's public health training programme was included as a benchmark with its long history and focus on prevention amid demographic and epidemiological changes. Study design A mixed-method descriptive study that maps, compares, and analyses public health training structures and alignment with the World Health Organisation Essential Public Health Functions (EPHFs) across multiple countries. Methods A two-stage approach was used: a scoping review of peer-reviewed literature on core public health professional and specialist training linked to national authority bodies, followed by national and institutional data curation by subject matter experts on national policies, training curricula, and institutional programmes. Results Training structures, delivery models, duration, and certification varied widely. Most ASEAN countries offered separate training pathways for medical and non-medical professionals, with programmes at bachelor's, master's, and doctoral programmes. The UK provided a unified, competency-based training scheme open to both groups, including a master's and a portfolio route for specialist recognition. Training that covered the 12 EPHFs had been delivered through academic, workplace, or combined models. Public health workforce plans existed in most countries except for Brunei Darussalam and Vietnam. Conclusions This first systematic analysis highlights the diversity of public health training in the ASEAN region, reflecting differences in institutional maturity, policies, resources, and population health contexts. Strengthening the public health workforce requires increased regional collaboration, investment, and harmonised competency-based training. Leveraging the experience of the UK model, ASEAN can work towards standardised curricula and expanded access through multisectoral entry pathways, enabling coordinated workforce development aligned with health priorities.Item Metadata only Causes of death in rural southeast Asia by electronic verbal autopsy: a population-based observational study(2025-12-01) Htun N.S.N.; Phommasone K.; Perrone C.; Phyo A.P.; Sen A.; Vanna M.; Tripura R.; Kabir N.; Islam M.A.; Wirachonphaophong J.; Panyadee P.; Chandna A.; Boonyoung S.; Lek D.; Pongvongsa T.; Mayxay M.; Kamadod R.; Day N.P.J.; Morris S.K.; Ashley E.A.; Jha P.; Lee S.J.; Lubell Y.; Peto T.J.; Htun N.S.N.; Mahidol UniversityBACKGROUND: In low-income and middle-income countries in southeast Asia, most deaths occur outside of the health-care system without a medically certified cause of death. We did a verbal autopsy study to determine the underlying causes of death in rural areas of the region and to estimate premature mortality using years of life lost (YLLs). METHODS: In this population-based observational study, we conducted electronic verbal autopsy surveys for reported deaths in 510 villages in Bangladesh, Cambodia, Laos, Myanmar, and Thailand from 2021 to 2024. With the WHO 2016 verbal autopsy questionnaire, trained fieldworkers conducted interviews, and local physicians independently assigned causes of death by ICD-10 codes. Causes of death were ranked based on cause-specific mortality fractions (CSMFs), and YLLs calculated using corresponding national life expectancy. FINDINGS: Over 90% of reported deaths had a verbal autopsy administered. Among 3413 deaths, 2052 (60%) were male and 1361 (40%) were female, and 3245 (95%) were older than 12 years. Across sites, 64-86% of deaths occurred at home. Non-communicable diseases were the leading causes of death, ranging from 54% in Laos to 70% in Cambodia, with cardiovascular, cerebrovascular, cancer, and digestive conditions being the most common. Maternal, nutritional, and communicable diseases, mainly respiratory infections, diarrhoea, and tuberculosis, accounted for 11-26% of deaths across the sites. Accidents and injuries comprised 7-13% and ranked among the top five causes. Major gaps in death documentation persist across all countries, whereas disease-specific causes of death varied between sites. Non-communicable diseases accounted for the majority of YLLs, representing between 56% and 65% across the five countries. INTERPRETATION: This multicountry study highlighted the significant burden of non-communicable diseases in rural southeast Asia, alongside persistent communicable diseases, emphasising the need for better mortality data and health-care access to reduce this dual burden. FUNDING: Wellcome Trust. TRANSLATIONS: For the Myanmar, Karen, Bangla, Thai, Lao and Khmer translations of the abstract see Supplementary Materials section.Item Metadata only Changing genetic profiles of Plasmodium falciparum piperaquine resistance in Southeast Asia over 25 years(2026-04-01) Srisutham S.; Suwannasin K.; Saejeng A.; Khantikul N.; Sugaram R.; Phyo A.P.; Proux S.; Pongvongsa T.; Nguon C.; Tripura R.; Chau N.H.; Lek D.; Trung N.H.D.; Peto T.J.; Callery J.J.; van der Pluijm R.W.; Amaratunga C.; Dhorda M.; von Seidlein L.; Mayxay M.; Thuy-Nhien N.T.; Newton P.N.; Day N.P.J.; Ashley E.A.; Nosten F.H.; Smithuis F.M.; White N.J.; Dondorp A.M.; Imwong M.; Srisutham S.; Mahidol UniversityPiperaquine resistance in Plasmodium falciparum has emerged in Southeast Asia and is strongly associated with mutations in the pfcrt gene and amplification of pfplasmepsin2/3. This study assessed the frequency of pfcrt mutations and pfplasmepsin2/3 gene amplifications across Southeast Asia over 25 years, which is critical for tracking resistant parasites. A total of 898 P. falciparum isolates collected from Thailand, Myanmar, Cambodia, Laos, and Vietnam between 1995 and 2023 were analyzed for pfcrt mutations, pfplasmepsin2 copy number, and microsatellite variation around the pfcrt locus. During the study period, pfcrt mutations in Cambodia across the study period showed that H97Y had the highest prevalence at 15%, followed by T93S at 8%, while I218F was common in 24% of specimens in Srisaket and Ubon in Thailand at 24.44%, followed by G353V at 20%, T93S at 17%, F145I at 13%, and H97Y at 4%. In Tak, Thailand, a mutation was found only in 1995 with 40% at I218F and the remaining wild-type. Yala in Thailand and Kayin State in Myanmar remained wild-type. Vietnam showed frequent T93S at 21%. The prevalence of pfcrt mutations observed in this study changed throughout the study period. Over 65% of parasites with pfcrt mutations at positions 93, 97, 145, 218, 343, and 353 also had pfplasmepsin2 amplification. Temporal analysis revealed that in Cambodia, pfplasmepsin2 CNV emerged first, peaking at 88% prevalence in 2015 after the introduction of DHA-piperaquine, with the subsequent increase of pfcrt mutations H97Y and G353V. In Eastern Thailand, both pfcrt mutations and pfplasmepsin2 CNV were highly prevalent, exceeding 70% during 2015–2018. In Vietnam, rapid increases in both markers were observed after 2012, reaching peak by 2017. Microsatellite analysis revealed reduced genetic diversity around mutant pfcrt alleles, indicating selective sweeps. This study demonstrates that frequencies of pfcrt mutations and pfplasmepsin2 amplification linked to piperaquine resistance have changed over time, highlighting the importance of ongoing genetic monitoring to inform strategies for preserving artemisinin-based combination therapy efficacy.Item Metadata only Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia(2022-07-15) Cutts J.C.; O’Flaherty K.; Zaloumis S.G.; Ashley E.A.; Chan J.A.; Onyamboko M.A.; Fanello C.; Dondorp A.M.; Day N.P.; Phyo A.P.; Dhorda M.; Imwong M.; Fairhurst R.M.; Lim P.; Amaratunga C.; Pukrittayakamee S.; Hien T.T.; Htut Y.; Mayxay M.; Abdul Faiz M.; Takashima E.; Tsuboi T.; Beeson J.G.; Nosten F.; Simpson J.A.; White N.J.; Fowkes F.J.I.; Mahidol UniversityBackground. Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low-transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance re yet to be quantified. Methods. In an artemisinin therapeutic efficacy study, antibodies to 12 pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in the Democratic Republic of Congo (DRC) and compared with responses in patients from Asian sites, described elsewhere. Results. Parasite clearance half-life was shorter in DRC patients (median, 2 hours) compared with most Asian sites (median, 2–7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive, −0.14 to +0.40 hour) in DRC patients. Conclusions. In DRC, where artemisinin remains highly effective, the substantially shorter parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied.Item Metadata only Comparison of in vitro antibiotic susceptibility testing of R. typhi using plaque assay and quantitative real-time PCR(2026-06-02) Phuklia W.; Padith K.; Farris C.M.; Richards A.L.; Phommasone K.; Mayxay M.; Mukaka M.; Robinson M.T.; Newton P.N.; Day N.P.J.; Ashley E.A.; Phuklia W.; Mahidol UniversityMurine typhus, caused by Rickettsia typhi, is a globally distributed flea-borne disease. Antimicrobial susceptibility data are largely based on reference strains, with little evaluation of variability across clinical isolates. The plaque assay, the gold standard for antibiotic susceptibility testing, requires up to 14 days to complete. Quantitative real-time PCR (qPCR) offers a rapid alternative for determining minimum inhibitory concentrations (MICs). Although qPCR-based susceptibility testing has been described, formal statistical assessment of agreement between methods remains limited. We estimated the MICs for azithromycin, doxycycline, and amoxicillin using qPCR and plaque assay on 24 R. typhi isolates (8 laboratory strains and 16 Lao clinical isolates) cultured in Vero cells. Heat-inactivated R. typhi (56°C, 30 min) served as a control. MIC was defined as the lowest concentration preventing plaque formation (plaque assay) or producing a Ct value greater than or equal to that of the heat-inactivated sample (qPCR). The mean MIC from three independent experiments was taken to represent each isolate. Agreement between methods was assessed using Bland-Altman analysis. Median qPCR MICs (MIC50) of all isolates were 0.130 mg/L (IQR, 0.104-0.240 mg/L) for azithromycin, 0.130 mg/L (IQR, 0.065-0.224 mg/L) for doxycycline, and 256 mg/L (IQR, 234.7-341.3 mg/L) for amoxicillin. Corresponding plaque assay MICs50 were 0.383 mg/L (IQR, 0.194-0.807 mg/L), 0.037 mg/L (IQR, 0.026-0.073 mg/L), and 170.7 mg/L (IQR, 112-256 mg/L), respectively. Bias was -0.3452 (-1.146, 0.4558) for azithromycin, 0.0969 (-0.2297, 0.4235) for doxycycline, and 85.33 (-187.3, 358) for amoxicillin. These findings demonstrate inter-isolate variability and quantitative agreement between methods.IMPORTANCEMurine typhus is a treatable febrile illness caused by Rickettsia typhi, transmitted to humans via fleas. The plaque assay, which detects bacterial-induced host cell death in the presence or absence of antibiotics, is the reference method for testing drug susceptibility. However, the method requires approximately 2 weeks to obtain results. Detection of bacterial nucleic acid provides an alternative laboratory approach that reduces the assay duration to approximately 1 week, thereby improving research efficiency and throughput when testing multiple isolates. Compared with plaque assays, quantitative real-time PCR allows downstream analysis following sample inactivation, reducing prolonged high-containment handling. In this study, we compared the antibiotic susceptibility of 24 R. typhi isolates using both methods. We tested antibiotics commonly used to treat R. typhi infection (doxycycline and azithromycin), along with amoxicillin as a negative control. Both showed comparable results for all antibiotics tested, further supporting nucleic acid detection as a reliable and faster alternative.Item Metadata only Correction to: Malaria epidemiology, surveillance and response for elimination in Lao PDR (Infectious Diseases of Poverty, (2024), 13, 1, (35), 10.1186/s40249-024-01202-7)(2024-12-01) Rotejanaprasert C.; Malaphone V.; Mayxay M.; Chindavongsa K.; Banouvong V.; Khamlome B.; Vilay P.; Vanisavaeth V.; Maude R.J.; Rotejanaprasert C.; Mahidol UniversityFollowing publication of the original article [1], the authors reported a typo in one of the author names. The name “Mayfong Maysay” should be corrected to “Mayfong Mayxay”. The original article [1] has been updated.Item Metadata only Cost-effectiveness analysis of typhoid vaccination in Lao PDR(2023-12-01) Soukavong M.; Luangasanatip N.; Chanthavilay P.; Teerawattananon Y.; Dabak S.V.; Pan-ngum W.; Roberts T.; Ashley E.A.; Mayxay M.; Mahidol UniversityBackground: Typhoid vaccination has been shown to be an effective intervention to prevent enteric fever and is under consideration for inclusion in the national immunization program in Lao PDR. Methods: A cost-utility analysis was performed using an age-structured static decision tree model to estimate the costs and health outcomes of introducing TCV. Vaccination strategies combined with five delivery approaches in different age groups compared to no vaccination were considered from the societal perspective, using the Gavi price of 1.5 USD per dose. The vaccination program was considered to be cost-effective if the incremental cost-effectiveness ratio was less than a threshold of 1 GDP per capita for Lao PDR, equivalent to USD 2,535 in 2020. Results: In the model, we estimated 172.2 cases of enteric fever, with 1.3 deaths and a total treatment cost of USD 7,244, based on a birth cohort of 164,662 births without TCV vaccination that was followed over their lifetime. To implement a TCV vaccination program over the lifetime horizon, the estimated cost of the vaccine and administration costs would be between USD 470,934 and USD 919,186. Implementation of the TCV vaccination program would prevent between 14 and 106 cases and 0.1 to 0.8 deaths. None of the vaccination programs appeared to be cost-effective. Conclusions: Inclusion of TCV in the national vaccination program in Lao PDR would only be cost-effective if the true typhoid incidence is 25-times higher than our current estimate.Item Metadata only Estimating scrub typhus and murine typhus incidence among adolescents and adults in Yangon, Myanmar(2025-01-01) Oo W.T.; Bowhay T.R.; Myat T.O.; Htike W.W.; Lwin K.T.; Blacksell S.D.; Tanganuchitcharnchai A.; Mayxay M.; Newton P.N.; Robinson M.T.; Ussher J.E.; Murdoch D.R.; Win H.H.; Crump J.A.; Oo W.T.; Mahidol UniversityObjectives: Rickettsioses are frequent causes of treatable febrile illness in Southeast Asia, including Myanmar. Accurate estimates of the incidence of rickettsioses are needed to inform investments in disease prevention and control. We sought to estimate the incidence of rickettsioses among adults and adolescents by combining sentinel hospital surveillance with a healthcare utilisation survey in Yangon, Myanmar. Methods: We conducted a household-based healthcare utilisation survey in the Yangon Region from 12 March through 5 April 2018. Multipliers derived from this survey were then applied to scrub typhus, murine typhus, and spotted fever group rickettsioses infections identified from a study of adolescent and adult community-onset febrile illness done from 5 October 2015 through 4 October 2016 at Yangon General Hospital to estimate disease incidence. Acute serum was collected at enrolment and convalescent serum 14–30 days after enrolment. Confirmed acute scrub typhus, murine typhus, and spotted fever group infections were diagnosed by a ≥ 4-fold rise between acute and convalescent immunofluorescent antibody test titre to Orientia tsutsugamushi pooled Karp, Kato, and Gilliam antigens; Rickettsia typhi Wilmington strain; and Rickettsia honei and Rickettsia conorii antigens, respectively. Results: After applying multipliers, we estimated the overall annual incidence of acute scrub typhus among adolescents and adults in the Yangon Region at 211 cases per 100,000 persons, and the overall estimate of acute murine typhus among adults and adolescents was 44 cases per 100,000 persons per year for 2015–2016. There were no confirmed spotted fever group infections. Conclusions: We provide the first estimates of scrub typhus and murine typhus community incidence in Myanmar. Similar research in children and from other parts of Myanmar, as well as studies of illness duration, complications, and deaths, is needed to estimate the disease burden.Item Metadata only Evaluation of trends in hospital antimicrobial use in the Lao PDR using repeated point-prevalence surveys-evidence to improve treatment guideline use(2022-10-01) Chansamouth V.; Chommanam D.; Roberts T.; Keomany S.; Paphasiri V.; Phamisith C.; Sengsavang S.; Detleuxay K.; Phoutsavath P.; Bouthavong S.; Douangnouvong A.; Vongsouvath M.; Rattana S.; Keohavong B.; Day N.P.J.; Turner P.; van Doorn H.R.; Mayxay M.; Ashley E.A.; Newton P.N.; Mahidol UniversityBackground: Antimicrobial use (AMU) is a key driver of antimicrobial resistance (AMR). There are few data on AMU, to inform optimizing antibiotic stewardship, in the Lao PDR (Laos). Methods: Point prevalence surveys (PPS) of AMU were conducted at four-month intervals in six general hospitals across Laos from 2017 to 2020, using modified Global-PPS data collection tools. The surveys focused on AMU amongst hospitalized inpatients. Findings: The overall prevalence of inpatient AMU was 71% (4,377/6,188), varying by hospital and survey round from 50·4% (135/268) to 88·4% (61/69). Of 4,377 patients, 44% received >one antimicrobial. The total number of prescriptions assessed was 6,555. Ceftriaxone was the most commonly used (39·6%) antimicrobial, followed by metronidazole (17%) and gentamicin (10%). Pneumonia was the most common diagnosis among those prescribed antimicrobials in both children aged ≤5 years (29% among aged ≤1 year and 27% among aged >1 to ≤5years) and adults aged ≥15 years at 9%. The percentage of antimicrobial use compliant with local treatment guidelines was 26%; inappropriate use was mainly found for surgical prophylaxis (99%). Adult patients received ACCESS group antimicrobials less commonly than children (47% vs 63%, p-value<0·0001). Most WATCH group prescriptions (99%) were without a microbiological indication. Interpretation: AMU among hospitalized patients in Laos is high with frequent inappropriate use of antimicrobials, especially as surgical prophylaxis. Continued monitoring and enhanced antimicrobial stewardship interventions are needed in Lao hospitals. Funding: The Wellcome Trust [Grant numbers 220211/Z/20/Z and 214207/Z/18/Z] and bioMérieux.Item Metadata only Forensic investigation of falsified antimalarials using isotope ratio mass spectrometry: a pilot investigation(2024-12-01) Newton P.N.; Chesson L.A.; Mayxay M.; Dondorp A.; Tabernero P.; Howa J.D.; Cerling T.E.; Newton P.N.; Mahidol UniversityWe explored whether isotope ratio mass spectrometry (IRMS) is useful to investigate the origin of falsified antimalarials. Forty-four falsified and genuine antimalarial samples (artesunate, artemether-lumefantrine, dihydroartemisinin-piperaquine and sulphamethopyrazine-pyrimethamine) were analyzed in bulk for carbon (C), nitrogen (N), and oxygen (O) element concentrations and stable isotope ratios. The insoluble fraction (“starch”) was extracted from 26 samples and analyzed. Samples of known geographical origin maize, a common source of excipient starch, were used to produce a comparison dataset to predict starch source. In both an initial (n = 18) and a follow-on set of samples that contained/claimed to contain artesunate/artemether (n = 26), falsified antimalarials had a range of C concentrations less than genuine comparator antimalarials and δ13C values higher than genuine comparators. The δ13C values of falsified antimalarials suggested that C4 plant-based organic material (e.g., starch derived from maize) had been included. Using the known-origin maize samples, predictions for growth water δ18O values for the extracted “starch” ranged from − 6.10 to − 1.62‰. These findings suggest that IRMS may be a useful tool for profiling falsified antimalarials. We found that C4 ingredients were exclusively used in falsified antimalarials versus genuine antimalarials, and that it may be possible to predict potential growth water δ18O values for the starch present in falsified antimalarials.Item Metadata only Forest malaria and prospects for anti-malarial chemoprophylaxis among forest goers: findings from a qualitative study in Lao PDR(2022-12-01) Jongdeepaisal M.; Inthasone S.; Khonputsa P.; Malaphone V.; Pongsoipetch K.; Pongvongsa T.; Mayxay M.; Chindavongsa K.; Pell C.; Maude R.J.; Mahidol UniversityBackground: Despite significant decline in malarial incidence and mortality in countries across the Greater Mekong Subregion, the disease remains a public health challenge in the region; transmission continues mainly among people who visit forests in remote areas, often along international borders, where access to primary healthcare is limited. In the absence of effective vector-control measures and limited exposure periods, malaria chemoprophylaxis has been proposed as a strategy to protect forest goers. As a rarely used approach for indigenous populations, questions remain about its feasibility and acceptability. Drawing on in-depth interviews with forest goers and stakeholders, this article examines opportunities and challenges for implementation of anti-malarial chemoprophylaxis for forest goers in Lao PDR. Methods: In-depth interviews were conducted with 16 forest goers and 15 stakeholders in Savannakhet province, Lao PDR. Interview topics included experience of malaria prevention and health services, and perceptions of prophylaxis as a potential component of malaria elimination strategy. The interviews were transcribed and coded using inductive and deductive approaches for qualitative thematic analysis. Results: In ethnically and geographically diverse villages, awareness of malaria risk prompts forest goers to protect themselves, albeit sub-optimally using available preventive measures. Stakeholders highlighted challenges for targeting at-risk populations and approaches to address forest malaria in southern Lao PDR. Among policymakers, choice and cost of anti-malarials, particularly their efficacy and source of funding, were key considerations for the feasibility of malaria prophylaxis. Acceptability of prophylaxis among forest goers was also influenced by the complexity of the regimen, including the number of tablets and timing of doses. Implementation of prophylaxis may be affected by a lack of transportation and communication barriers in remote communities. Conclusion: Adding prophylaxis to existing malaria control activities requires strengthening the capacity of local health workers in Lao PDR. Ideally, this would be part of an integrated approach that includes strategies to address the other febrile illnesses that forest goers describe as priority health concerns. The prophylactic regimen also requires careful consideration in terms of effectiveness and simplicity of dosing.Item Metadata only From fragmentation to integration: regional health governance in southeast Asia(2026-01-01) Wang J.; Feng Y.; Liu Y.; Wang M.; Voo T.C.; Tuan T.D.; Baja E.S.; Ong S.K.; Wai Hoe V.C.; Thepanondh S.; Chhorvann C.; Meliala A.; Win H.H.; Mayxay M.; Ren M.; Jin Y.; Wang J.; Mahidol UniversitySoutheast Asia’s regional health governance has evolved into a dense but weakly integrated system of overlapping institutions. This Health Policy paper maps the regional health governance of the Association of Southeast Asian Nations (ASEAN) as an evolving health regime complex, tracing the historical origins of regional health governance to the early 20th century and examining developments from 1980 to 2024. The study also identifies two structural features: functional specialisation along with persistent fragmentation and structural asymmetry, in which external actors dominate technical and agenda-setting roles while ASEAN retains coordination authority. Although recent reforms under the ASEAN Post-2015 Health Development Agenda have improved institutional alignment, system-wide coherence remains poor. Strengthening regional health governance will require institutional rationalisation to reduce duplication and strengthen underdeveloped functions, alongside a rebalancing of external engagement to restore regional ownership of policy priorities. The analytical approach developed in this Health Policy paper offers a transferable framework for other regions facing institutional proliferation. Policy efforts should shift from expanding arrangements towards managing complexity through coordination, functional differentiation, and clearer authority structures.Item Metadata only Genetic surveillance of Plasmodium falciparum populations following treatment policy revisions in the Greater Mekong Subregion(2025-12-01) Wasakul V.; Verschuuren T.D.; Thuy-Nhien N.; Booth E.; Quang H.H.; Thang N.D.; Chindavongsa K.; Sovannaroth S.; Banouvong V.; Sengsavath V.; Mayxay M.; Tuyen N.T.K.; Phuong V.N.L.; Duc Trung P.; Gonçalves S.; Chen S.; Phalivong S.; Xayvanghang S.; Mahaphontrakoon S.; Pearson R.D.; Newton P.N.; Maude R.J.; Ashley E.A.; Ariani C.V.; Simpson V.J.; Day N.P.; Dondorp A.M.; Miotto O.; Wasakul V.; Mahidol UniversityGenetic surveillance of Plasmodium falciparum (Pf) can track antimalarial-resistant strains, to inform decision-making by National Malaria Control Programmes (NMCPs). The GenRe-Mekong project prospectively collected 5982 samples in the Greater Mekong Subregion (GMS) between 2017 and 2022, genotyping drug resistance markers, and barcodes that recapitulate genetic variation. Genotypes were analyzed with the grcMalaria R package, first described in this paper, to translate genetic epidemiology data into actionable visual information. Since 2020, Pf incidences decreased rapidly, accompanied by a decline of dihydroartemisinin-piperaquine (DHA-PPQ) resistant lineages, previously dominant in the eastern GMS. The frequency of plasmepsin2/3 amplifications, conferring piperaquine resistance, dropped from 62% in 2017-2019 to 2% in 2022, coinciding with a switch in frontline therapy in Cambodia, Thailand, and Vietnam. While regional artemisinin resistance levels remained high, no evidence of emerging mefloquine resistance was found. Routine genetic surveillance proved valuable in monitoring rapid parasite population changes in response to public health interventions, providing actionable information for NMCPs.
- «
- 1 (current)
- 2
- 3
- »
